Be part of the knowledge.™

Nephrology

779

LikeLikedUnlike

1-15 of 138

Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CE
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
- Antoine Lanot, MD, PhD
  Peer
- Gil Yosipovitch, MD
  Peer
0.25 credits
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CE
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Richard Lafayette, MD, FACP
  Peer
- Ankana Daga, MD
  Peer
0.25 credits
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- Antoine Lanot, MD, PhD
  Peer
- Gil Yosipovitch, MD
  Peer
0.25 credits
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
CME/CE
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
- Jay B. Wish, MD
  Peer
1.00 credits
MinuteCE®
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
- Richard Lafayette, MD, FACP
  Peer
- Dana Rizk, MD
  Peer
- Hong Zhang
  Peer
- Suzuki Yusuke, MD, PhD
  Peer
1.00 credits 9 episodes
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
- Richard Lafayette, MD, FACP
  Peer
1.00 program credits
advertisement
APRIL Uncovered: An Upstream Driver in IgAN
MinuteCE®
APRIL Uncovered: An Upstream Driver in IgAN
- Dana Rizk, MD
  Peer
- Hong Zhang
  Peer
1.00 program credits
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
- Suzuki Yusuke, MD, PhD
  Peer
- Dana Rizk, MD
  Peer
1.00 program credits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
- Dana Rizk, MD
  Peer
- Suzuki Yusuke, MD, PhD
  Peer
1.00 program credits
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
- Hong Zhang
  Peer
1.00 program credits
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®
Emerging Evidence: IgAN Disease-Modifying Agents
- Richard Lafayette, MD, FACP
  Peer
- Hong Zhang
  Peer
1.00 program credits
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
- Richard Lafayette, MD, FACP
  Peer
- Hong Zhang
  Peer
1.00 program credits
advertisement
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
- Richard Lafayette, MD, FACP
  Peer
- Suzuki Yusuke, MD, PhD
  Peer
1.00 program credits
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
- Richard Lafayette, MD, FACP
  Peer
- Suzuki Yusuke, MD, PhD
  Peer
1.00 program credits
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
- Jonathan Barratt, MD, PhD
  Peer
0.25 credits

Program Chapters

Segment Chapters

Playlist:

Recommended